FSCPX

FSCPX is a potent and selective irreversible antagonist of A1 adenosine receptor (A1AR), with low nanomolar potency for binding to the A1AR. FSCPX could modify the effect of NBTI, a nucleoside transport inhibitor, by reducing the interstitial adenosine level in the guinea pig atrium[1][2].

Product Specifications

CAS Number

[156547-56-7]

Product Name Alternative

MK5435

UNSPSC

12352005

Target

Adenosine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/fscpx.html

Purity

99.72

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(OCCCN(C(N1CCC)=O)C2=C(N=C(C3CCCC3)N2)C1=O)C4=CC=C(S(=O)(F)=O)C=C4

Molecular Formula

C23H27FN4O6S

Molecular Weight

506.55

References & Citations

[1]Beauglehole AR, et, al. New irreversible adenosine A (1) antagonists based on FSCPX. Bioorg Med Chem Lett. 2002 Nov 4; 12 (21) : 3179-82.|[2]Erdei T, et, al. FSCPX, a Chemical Widely Used as an Irreversible A₁ Adenosine Receptor Antagonist, Modifies the Effect of NBTI, a Nucleoside Transport Inhibitor, by Reducing the Interstitial Adenosine Level in the Guinea Pig Atrium. Molecules. 2018 Aug 30; 23 (9) :2186.|[3]Lee HT, et, al. Renal tubule necrosis and apoptosis modulation by A1 adenosine receptor expression. Kidney Int. 2007 Jun;71 (12) :1249-61.